Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA

Executive Summary

An upcoming NDA filing for Hemispherx' chronic fatigue syndrome agent Ampligen may offer a sensitive case for FDA as it implements Commissioner McClellan's "strategic plan" for the agency

You may also be interested in...



Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews

FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.

Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews

FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.

House Committee Watching Genasense; Show Of Force During FDA Review

The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense

Related Content

UsernamePublicRestriction

Register

PS043491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel